[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 394 pages | ID: C2D0D77932A3EN
Global Markets Direct

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2022, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 17, 18, 3, 55, 24 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) - Overview
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
Featured News & Press Releases
Jul 11, 2022: Algernon Pharmaceuticals provides update on its planned phase 1 repirinast chronic kidney disease study
Jun 30, 2022: Kerendia (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes
Jun 28, 2022: Bayer’s KERENDIA (finerenone) receives new recommendations from American Diabetes Association for improving cardiovascular outcomes and managing patients with chronic kidney disease associated with type 2 diabetes
Jun 23, 2022: ProKidney corroborates the mechanism of action of REACT with cell marker analysis in patients with diabetic chronic kidney disease
Jun 15, 2022: ProKidney announces manufacturing efficiency initiatives and supply chain streamlining expected to reduce REACT Manufacturing Costs
Jun 07, 2022: Observed safety profile supports bilateral dosing of ProKidney’s REACT - 007 update
Jun 05, 2022: Bayer to present new Kerendia (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes
Jun 01, 2022: CinCor Pharma doses first patient in phase 2 FigHTN-CKD trial evaluating the selective aldosterone synthase inhibitor baxdrostat (CIN-107) in patients with uncontrolled hypertension and chronic kidney disease
May 23, 2022: New data support renal and cardiovascular benefits of Kerendia (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes
May 17, 2022: Bayer to present new Kerendia (finerenone) data from comprehensive clinical trial program in chronic kidney disease and type 2 diabetes
May 03, 2022: ProKidney highlights key registrational program elements supporting advancement of REACT
Apr 26, 2022: Algernon Pharmaceuticals announces lead chronic kidney disease drug repirinast reduced fibrosis by 56% in a preclinical NASH study
Apr 13, 2022: Renibus Therapeutics strengthens IP position with additional US patent
Apr 12, 2022: ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT
Apr 12, 2022: Caladrius Biosciences treats first patient in the phase 1b trial of CLBS201 for the treatment of diabetic kidney disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AdAlta Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Anagenics Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angiotensin Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aria Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Asahi Kasei Pharma Corp, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ashvattha Therapeutics LLC, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BerGenBio ASA, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Caladrius Biosciences Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ceptur Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chinook Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CinCor Pharma Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cinkate Corp, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Coegin Pharma AS, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Daiichi Sankyo Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DJS Antibodies Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eagle Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Co, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ennovabio, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evopoint Bioscience Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec SE, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Future Medicine Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G&P Bioscience Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G3 Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gila Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Goldilocks Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gubra ApS, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Helixmith Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Hybridize Pharma BV, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Icagen Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by iCELL Biotechnology Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by INVENT Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ionis Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Jnana Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP Biosciences Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kibow Biotech Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KidneyCure Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Liminal BioSciences Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lung Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Maze Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by MD Healthcare Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by MedBiome Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Meridigen Biotech Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by NovMetaPharma Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novo Nordisk AS, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Oisin Biotechnologies, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Oneness Biotech Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Orgenesis Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OrthoTrophix Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Pharmaxis Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Pharmicell Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Poxel SA, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProKidney LLC, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Purespring Therapeutics Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RAGE Biotech Pty Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Rege Nephro Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reliance Life Sciences Pvt Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Renibus Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Scohia Pharma Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Senda Biosciences Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Senolytic Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sentien Biotechnologies Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Suzhou Regend Therapeutics Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by TagCyx Biotechnologies, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicocell Biomed Co Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicycive Therapeutics Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicyte AG, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vertex Pharmaceuticals Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vidasym Inc, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vivazome Therapeutics Pty Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vivoryon Therapeutics NV, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Zydus Lifesciences Ltd, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, 2022
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, 2022 (Contd..2)
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications